Ribo Life Science to Showcase Extrahepatic Drug Delivery Innovations at RNA Leaders Europe Conference

Ribo Life Science to Present Breakthrough in Drug Delivery at RNA Leaders Conference

On March 19, 2026, Suzhou Ribo Life Science Co., Ltd. (known as Ribo) is invited to present innovative findings related to extrahepatic drug delivery at the RNA Leaders Europe Conference taking place in Vienna, Austria. Ribo, publicly listed under stock code 6938 on the Hong Kong Stock Exchange, is a pioneering company in biopharmaceuticals, focusing on oligonucleotide therapies.

Ribo has recorded significant success with its flagship product, RiboGalSTAR™, systemically targeting liver-specific genes and currently overseeing seven programs in clinical development. Alongside this, the company has secured two major global collaborations and licensing agreements valued over $6 billion, which underscores its capacity for developing impactful therapies.

Continuing its innovative trajectory, Ribo's expansion into extrahepatic (outside the liver) drug delivery is facilitated by its proprietary RiboPepSTAR™ platform technology. This advancement enables targeted small interfering RNA (siRNA) delivery to key organs beyond the liver, with preclinical data indicating promising results. Ribo’s preclinical studies have shown successful targeting of the kidneys, with specific uptake observed in proximal tubules. Furthermore, the data reflect reduced mRNA levels across species, from rodents to non-human primates, validating its effectiveness across various disease models.

Currently, Ribo is not solely focusing on the kidneys; other promising drug candidates targeting conditions related to cardiovascular health, adipose tissue, muscle function, and the central nervous system are also in preclinical development stages. By pushing the boundaries of extrahepatic therapies, Ribo aims to provide innovative siRNA treatments to patients worldwide, enhancing therapeutic options for numerous diseases.

The upcoming presentation at the RNA Leaders Europe Conference is not only a significant event for Ribo but also a remarkable opportunity for stakeholders in the biopharmaceutical industry to witness cutting-edge breakthroughs in drug delivery methodologies. As Ribo progresses, the potential for new life-saving therapies is expanding with each innovation.

By showcasing such advancements, Ribo Life Science continues to position itself as a leader in RNA-targeted therapeutics, dedicated to improving patient outcomes and revolutionizing treatment paradigms in biomedicine. The anticipation surrounding their findings at the conference reflects the industry’s eagerness for novel solutions to complex medical challenges, grounding Ribo's commitment to transformative healthcare practices.

For further inquiries and information about Ribo Life Science, follow them at the RNA Leaders Europe Conference or check their official channels for the latest updates on their groundbreaking work in extrahepatic drug delivery.